Clinical

Dataset Information

0

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas


ABSTRACT: This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.

DISEASE(S): Rectum Cancer,Metastatic Colorectal Cancer,Rectal Neoplasms,Pancreas Cancer,Colon Cancer,Recurrent Colorectal Carcinoma,Colorectal Neoplasms,Pancreatic Neoplasms,Cancer

PROVIDER: 2230594 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2367476 | ecrin-mdr-crc
| 2366037 | ecrin-mdr-crc
| 2539239 | ecrin-mdr-crc
2020-07-25 | GSE155027 | GEO
| PRJNA940176 | ENA
| 2283240 | ecrin-mdr-crc
2023-04-28 | GSE227522 | GEO
| PRJNA623864 | ENA
2018-03-05 | GSE102277 | GEO
2015-11-23 | E-GEOD-51817 | biostudies-arrayexpress